A recent study: Ustekinumab is associated with superior effectiveness
outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. VBC Biemans et al. Aliment Pharmacol Ther 2020; 52: 123-134. Thanks to Ben Gold for this reference.
Methods: Crohn´s disease patients, who failed anti-TNF treatment and started
vedolizumab or ustekinumab in standard care as second-line biological, were
identified in the observational prospective Dutch Initiative on Crohn and
Colitis Registry. 128 vedolizumab- and 85 ustekinumab-treated patients fulfilled
the inclusion criteria. Median age in the cohorts were 37 and 39 respectively.
Key findings (at 52 weeks):
- After adjusting for confounders, ustekinumab-treated patients were more likely to achieve corticosteroid-free clinical remission (odds ratio [OR]: 2.58, 95% CI: 1.36-4.90, P = 0.004), biochemical remission (OR: 2.34, 95% CI: 1.10-4.96, P = 0.027), and combined corticosteroid-free clinical and biochemical remission (OR: 2.74, 95% CI: 1.23-6.09, P = 0.014).
- Safety outcomes (infections: OR: 1.26, 95% CI: 0.63-2.54, P = 0.517; adverse events: OR: 1.33, 95% CI: 0.62-2.81, P = 0.464; hospitalisations: OR: 0.67, 95% CI: 0.32-1.39, P = 0.282) were comparable between the two groups
My take: This study indicates that ustekinumab is likely a more effective 2nd line agent for Crohn’s disease.
Related blog posts:
- Expert Guidance on Current IBD Mgt (2020)
- Expert Guidance on Inflammatory Bowel Disease (Part 3)
- Expert Guidance on Inflammatory Bowel Disease (Part 2)
Pingback: Comparative Efficacy: Vedolizumab vs Anti-TNF Agents | gutsandgrowth
Pingback: “Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease” & 14% of U.S. Infected with COVID-19 | gutsandgrowth
Pingback: Ustekinumab for Refractory Pediatric Ulcerative Colitis and Updated Adalimumab Dosing | gutsandgrowth
Pingback: Encouraging Safety Data for Ustekinumab & ESPGHAN Obesity Position Paper | gutsandgrowth
Pingback: Ustekinumab in Pediatric Patients and More on VTE Prophylaxis | gutsandgrowth
Pingback: Ustekinumab vs Adalimumab: Head-to-Head Study | gutsandgrowth